MedGenome to launch genetic test to diagnose FSHD1

MedGenome to launch genetic test to diagnose FSHD1
ET HealthWorld
Published onET HealthWorld
Publish Date28 February 2023
Reading time1 Min

Share on Social Links

Category

StockBeginner GuideAngel InvestingSME IPOEconomy MarketAIFInvestmentsMore

MedGenome Labs has announced the launch of its Optical Genome Mapping Test (OGM) for diagnosing Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1) in India to provide an assessment of the genetic changes in patients with FSHD1. The test can detect large-scale insertions and duplications, as well as more subtle changes in DNA that can cause FSHD1.

Tags

StockBeginner GuideAngel InvestingSME IPOEconomy MarketAIFInvestmentsMore

Stay Connected, Stay Informed –

Join Our

WhatsApp

Channel!

Don’t miss out on exclusive updates, market trends, and real-time investment opportunities. Be the first to know about the latest unlisted stocks, IPO announcements, and curated Fact Sheets, delivered straight to your WhatsApp.

Pre Ipo

Pre Ipo

Upcoming IPO

Upcoming IPO

Unicorn

Unicorn